文献速递自身免疫性与大疱性皮肤病

Dsg3肽偶联耐受性纳米颗粒治疗天疱疮的安全性、耐受性、药代动力学与药效学研究

Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus.
PubMed 文献 · Br J Dermatol · 2026-01-01

该首次人体开放标签I期试验评估了TPM203(四种纳米颗粒偶联的Dsg3免疫优势T细胞肽混合物)在17例无至中度疾病活动的寻常型天疱疮患者中的安全性、耐受性和药代动力学。TPM203静脉给药(单次递增剂量和多次剂量,每两周一次共三次)未发生严重或重度不良事件,并观察到Treg细胞增加、Th17.1和CD27+记忆B细胞减少、Dsg3特异性T细胞减少以及抗Dsg3 IgG诱导的角质形成细胞解离能力显著降低。

要点

  • TPM203在17例PV患者中安全且耐受良好,无严重或重度不良事件。
  • TPM203可增加Treg细胞并减少Th17.1和CD27+记忆B细胞。
  • 单次给药后第8周Dsg3特异性T细胞显著减少。

核心结论

  • TPM203首次人体给药安全且耐受良好,具有促进PV免疫耐受诱导的潜力,支持进一步临床开发。

研究设计与样本

  • 开放标签首次人体I期试验,纳入17例无至中度疾病活动的寻常型天疱疮患者,TPM203静脉给药采用单次递增剂量和多次剂量(每两周一次共三次)。

主要发现

  • 17例患者未发生任何严重或重度不良事件,也无治疗相关的PV恶化。
  • 药代动力学证实TPM203从循环中快速清除。
  • 合并剂量组分析显示Treg细胞增加,Th17.1和CD27+记忆B细胞减少。
  • 单次给药后第8周Dsg3特异性T细胞显著减少。
  • 三个较低单次递增剂量组的抗Dsg3 IgG水平呈下降趋势,多次给药后IgG诱导的角质形成细胞解离能力显著降低。

临床怎么用

  • TPM203作为纳米颗粒耐受原疗法,可能为PV提供安全且特异的免疫耐受诱导策略,需进一步临床开发验证。

局限性

  • 为开放标签首次人体I期试验,样本量较小(17例),部分终点为探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pemphigus vulgaris (PV) is a CD4+ T-cell-dependent autoantibody-mediated blistering disease associated with human leucocyte antigen (HLA) class II molecules. IgG autoantibodies against the primary autoantigen desmoglein 3 (Dsg3), a desmosomal adhesion protein on epidermal keratinocytes, cause loss of epidermal cell adhesion. OBJECTIVES: To assess the clinical applicability of an innovative nanoparticle platform for the induction of immune tolerance exploiting the natural tolerance potential of liver sinusoidal endothelial cells. An open-label first-in-human study was conducted with TPM203, a mixture of four nanoparticle-coupled immunodominant Dsg3 T-cell peptides. METHODS: The efficacy and mechanism of action of TPM203 were first tested in a humanized HLA-DRB1*0402-transgenic PV mouse model. In the clinical phase I trial, TPM203 was administered intravenously in patients with PV with no-to-moderate disease activity in single ascending and multiple doses (three doses of TPM203 two weeks apart). Primary endpoints included safety and tolerability. As a secondary endpoint, pharmacokinetics were assessed. Exploratory endpoints comprised changes in Dsg3-specific and bulk T- and B-cell frequencies, anti-Dsg3 IgG levels and autoantibody-induced keratinocyte dissociation. The trial was registered with EudraCT (2019-001727-12). RESULTS: In the PV mouse model, two administrations of TPM203 significantly reduced anti-Dsg3 IgG. On the cellular level, TPM203 led to a significant decrease in CD4+ T cells in the spleen, accompanied by increased frequencies of regulatory T (Treg) cells. In the clinical trial, the 17 patients with PV enrolled across single- and multiple-dose groups did not experience any serious or severe adverse events, or treatment-related PV worsening. Pharmacokinetics confirmed rapid TPM203 clearance from the circulation. Significant TPM203-induced modulations in bulk lymphocyte subsets included an increase in Treg cells, and reductions in T helper 17.1 and CD27+ memory B cells, when dose groups were combined for analysis. Dsg3-specific T cells were found to be significantly reduced at week 8 following single administration of TPM203. Anti-Dsg3 IgG levels trended downward in the three lower single ascending dose groups, while IgG-induced keratinocyte-dissociating capacity was significantly reduced after multiple doses. CONCLUSIONS: Administered for the first time in humans, TPM203 was shown to be a safe and well-tolerated nanoparticle-based therapeutic approach with the potential to promote tolerance induction in PV, justifying further clinical development in this and other autoimmune diseases. An author video to accompany this article is available online. Pemphigus is a rare but potentially life-threatening disease. It causes blisters to form on the skin, mouth and genitals. It can lead to the loss of body fluids and proteins. It is also associated with severe infections. Blisters are caused by ‘autoantibodies’ (misguided defence proteins in the immune system) that bind to a component of the skin called Dsg3. The autoantibodies are produced by specialized immune cells known as ‘B cells’ with the help of another group of immune cells called ‘T cells’. These cells play an important role in starting autoimmune responses. In this study, we tried to block the effects of T cells in pemphigus. We did this using ‘nanoparticles’ to deliver pieces of Dsg3 to the liver. These nanoparticles have the potential to inhibit (or stop) the misdirected immune response. We carried out a study in Germany, Italy and the UK and gave increasing doses of Dsg3-loaded nanoparticles to a group of 17 patients with the disease. We found that the treatment was well-tolerated by the patients. They did not experience any severe side effects. We also found changes in the patients’ blood. This provided the first hints that T cells and activated B cells that promote inflammation could be blocked, leading to a decrease in pemphigus autoantibodies. Our study findings suggest that Dsg3-loaded nanoparticles should be further developed. The aim would be to treat pemphigus, and maybe even other autoimmune diseases, in a safe and specific way.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Didona D, Hudemann C, Garn H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus. Br J Dermatol. 2026. PMID: 40795222. doi:10.1093/bjd/ljaf311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。